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This survey is performed to update knowledge about methods and trends in lung cancer
radiotherapy. A signiﬁcant development has been noticed in radiotherapeutic techniques,
but  also in the identiﬁcation of clinical prognostic factors. The improvement in the ther-
apeutic line includes: application of the four-dimensional computer tomography (4DCT),
taking advantage of positron emission tomography (PET-CT), designing of new computa-
tional algorithms, allowing more precise irradiation planning, development of treatment
precision veriﬁcation systems and introducing IMRT techniques in chest radiotherapy. TheBRT treatment outcomes have improved with high dose radiotherapy, but other fractionation
alternations have been investigated as well.
© 2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
using modern tools. The areas where particular developmentadiotherapy represents the basic method of treatment in
ung cancer. It is used at every stage of clinical advancement,
oth in the non-small cell (NSCLC) and the small-cell form
SCLC) of the cancer. According to epidemiological studies,
n developed countries 61–76% of all patients with NSCLC
equire one of radiotherapy forms at a certain stage of their
isease.1,2 At early stages of the disease advancement, in cases
hen the patient is not planned to undergo surgery, stereo-
actic radiotherapy is applied, in locally advanced stages,
adiochemotherapy or radical radiotherapy are used. In cases
f the disseminated disease or when the disease cannot be
adically treated for various medical reasons, radiotherapy
s employed as a palliative treatment. On the grounds of
he analysis of data obtained from SEER-17 data base and
∗ Corresponding author. Tel.: +48 71 3689499.
E-mail address: maciejczyk.a@dco.com.pl (A. Maciejczyk).
ttp://dx.doi.org/10.1016/j.rpor.2014.04.012
507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier Upresented during ASTRO conference, Kong et al. evaluated
the effect of radiotherapy on patients’ survival, compar-
ing techniques employed before and after 2004. Application
of radiotherapy was found to improve results of treatment
at all stages of advancement, with better results obtained
in the group treated after 2004, thus using more  modern
techniques.3
In recent years, a signiﬁcant progress has been observed
in radiotherapeutic techniques in general, with a signiﬁcant
increase in studies on the efﬁcacy of lung cancer radiotherapyhas been detected include progress in identiﬁcation of clini-
cal prognostic factors, allowing individualization of patient’s
treatment as well as improved quality of anatomic imaging
rban & Partner Sp. z o.o. All rights reserved.
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of the tumour and the regional lymph nodes, which results
in a precise deﬁnition of the target volume.4 Nevertheless,
from the point of view of a radiotherapist the most important
has been the improvement in the therapeutic line techno-
logical quality: application of the four-dimensional computer
tomography (4DCT), taking advantage of positron emission
tomography (PET-CT) studies in treatment planning, design-
ing of new computational algorithms, allowing more  precise
irradiation planning, development of treatment precision
veriﬁcation systems and alterations in the very implemen-
tation process in administration of the recommended dose.
Application of new technological solutions allowed to deliver
treatment in higher biological doses with retention of treat-
ment toxicity at a relatively low level.
1.  PET-CT
In patients with lung cancer the key examination, permitting
an improved quality of preliminary qualiﬁcation and radio-
therapy planning, is PET-CT with [18F]-FDG. Some prospective
studies revealed that introducing PET-CT before planned
radiotherapy disqualiﬁed radical treatment in 25–30% of the
patients, most frequently due to distant metastases.5,6 PET-
CT examination manifests high sensitivity in detection of
metastatic lymph nodes and distant metastases. This diag-
nostic accuracy allows to distinguish patients with lower
stage of advancement, in whom radical treatment (surgery
or local therapy) can be performed, from palliative patients.
The value of PET-CT in radiotherapy planning cannot be
overlooked either, as the tool which helps to deﬁne target
volumes. Numerous studies have accentuated that PET-CT
examination in planning of radiotherapy reduces the risk of
the geographic error, particularly in outlining the mediastinal
lymph nodes,7,8 but also in distinguishing the tumour from the
surrounding pulmonary atelectasis.9 The equipment used for
PET-CT examinations in radiotherapy must be appropriately
calibrated.10 The use of such imaging for planning requires
compliance with certain protocols, which specify not only
patient immobilization but also an appropriate interpretation
of obtained results.10,11 Quality of the image,  which is sup-
posed to be used for planning, can be improved by the use of
PET-CT equipment, which additionally records patient’s respi-
ratory cycles (4DPET-CT). This causes the blurring of image
patterns, resulting from patient’s respiratory movements, to
become reduced and in this way the region of metaboli-
cally active lesions within the lung can be better outlined.
Another difﬁcult issue is the manner in which PET-CT is used
for outlining the target volume. The most frequently used
method is qualitative visual evaluation of PET images (Qual-
itative Visual Method, QVM). The other approaches involve
an automated quantitative evaluation of the result: an arbi-
trary SUV level can be assumed, e.g. >2.5, and on this basis
the tumour can be located. However, the approach is difﬁ-
cult because no standard SUV value is deﬁned for malignant
tumours. Another method involves determination of a thresh-
old SUVmax value, expressed in percents, e.g. 40%, above
which the tumour region is outlined. No unequivocal data are
available which may suggest an optimal character of any of
these approaches. Therefore, the best solution requires theiotherapy 1 9 ( 2 0 1 4 ) 353–360
formation of an interdisciplinary team dealing with appro-
priate qualiﬁcation and treatment planning and in this way
direct cooperation with a nuclear medicine specialist. Only
such a cautious approach to the obtained results allows to
signiﬁcantly avoid systemic errors resulting from an improper
interpretation of the Images.10,12 Radiation Therapy Oncology
Group (RTOG) recommended the use of [18F]-FDG-PET-CT in
radiotherapy planning of patients with non-small cell lung
cancer already in 2003. Nevertheless, further investigations
are necessary to deﬁne the role of this examination with
higher accuracy, at least within the range of effects induced
by the therapy and the effect of PET on patients’ survival.
2.  Role  of  4DCT  in  RT  planning
The concept of using 4-dimensional computer tomography
(4DCT) for radiotherapy planning has been discussed for a long
time, due to the signiﬁcant and not always predictable mobil-
ity of chest organs. The idea of 4DCT involves scanning of the
patient using a spiral computer tomography, which is paral-
leled by the reception of signals recording the respiratory cycle.
Subsequently, the collected tomographic data are separated
for individual respiratory phases, with the resulting grouping
of CT images into a few series, reﬂecting shift of the tumor.13
Treatment planning based on 4DCT images requires the use of
an algorithm grouping CT images into separate image  sets, in
which oncologist-radiotherapist deﬁnes independent tumour
contours, which subsequently can be presented as a global
contour in a selected bin. At present, the use of 4DCT is rec-
ommended both in conventional fractionation,14 and in high
dose radiotherapy.15
Based on 4D tomography, a few concepts were introduced
for PTV deﬁning. They include internal tumour volume (ITV)-
PTVITV, modiﬁcation of ITV based on maximum intensity
projection (MIP)-PTVMIP, determination of PTV based on
respiratory gating-PTVGATING and the concept of midventilation-
PTVMidVen.
Determination of PTVITV involves outlining of a tumour
in 6–10 individual respiratory phases.16 Even if relatively pre-
cise, the method is time- and work-consuming and, therefore,
the potential for a faster contouring has been introduced as
a facilitation of the radiotherapist’s every day work, based
on automatic delineation of ITV using MIP.  MIP  projection
reﬂects maximum values of HU ascribed to voxels in the
volume restricted to tumour location while delineation of
the region itself takes place with an assistance of a speciﬁc
software,17 the so-called 3D IsoConture identifying marginal
HU values which detach tumour margins from the lung. This
allows restricting the time-consuming procedure of outlining
the tumour, but it also carries limitations in cases of tumours
situated close to the chest wall or mediastinum.
Radiotherapy using respiratory gating involves irradiation
of a tumour only at a certain stage of respiratory cycle,
most frequently at expiration, although breath-hold tech-
niques can also be applied. In order to implement this
concept special equipment is required, which reads out respi-
ratory movements of the patient, synchronizing them with
an accelerator.18 In order not to needlessly extend RT proce-
dure, 20–40% of the respiratory cycle time is used to create the
radiotherapy 1 9 ( 2 0 1 4 ) 353–360 355
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Fig. 1 – DVH for a target located in the lung. Dose
distribution obtained using two algorithms of PB and AAA,reports of practical oncology and 
TVGATING. The method allows to reduce the irradiated region
lthough its implementation takes 1–2 h.
A fully new approach is the mid-ventilation – PTVMidVen con-
ept, involving selection of the reference CT scan, in which
he tumour in the respiratory cycle is situated in the averaged
ime, determined on calculation of a weighted mean.19 This
eans that the tumour for a short period of time remains out
f the irradiated region. Such a solution seems to be particu-
arly interesting from the clinical point of view (a signiﬁcant
eduction of PTV region) but it requires further veriﬁcation and
afety of the approach should be checked.
Comparing the size of the target delineated on the 4DTCT
o the one created based on conventional free-breathing CT
PTVCONV), alterations are noted in the size of PTV region. It
hould be noted that in the conventional technique the size of
argins is estimated in line with the principle of probability.19
f PTVCONV is compared to PTVMidP and PTVGATING, a marked
eduction is noted in the irradiated region, particularly in
umours located in the lower parts of the lungs. In turn, deﬁni-
ion of PTVITV may additionally increase the region. However,
t should be stressed that prolonged time of implementing
espiration-gated radiotherapy is frequently tiresome for the
atient. Underberg et al. calculated that clinical justiﬁcation
or employing gating can be noted only when reduction of
TVGATING, as compared to PTVITV, amounts to at least 50%. In
ractice, in most of patients lower reduction of the volume is
oted and only in around 5% patients PTV reduction of clinical
igniﬁcance is encountered.17
.  Calculation  algorithms
orrect deﬁnition of the applied dose represents an important
lement of properly performed radiotherapy. The accuracy
nd correctness of estimating the dose using computer
ssisted calculations are linked to analysis involving the cur-
ently available algorithms which calculate the dose in regions
ommonly regarded as presenting difﬁculties in the calcula-
ion. Such a region involves tissues of low density, e.g. lungs,
urrounded by tissues of a normal (water-resembling) density.
t present, two principal types of algorithms are available:
ype A and the more  advanced type B. The type A includes the
lgorithms of Pencil Beam Convolution Model (PBC) used up
o date, which demonstrated dose distributions as much more
niform for targets surrounded by pulmonary tissue than the
imulatory Monte Carlo (MC) type B calculations. The high
nhomogeneity of doses in simulations reﬂected the inclusion
f dose transport from dispersed quants, the lower energy of
hich resulted in an inhomogenous distribution of the trans-
erred absorbed dose. MC  algorithms are thought to provide
 gold standard for dose calculation but they are not com-
only used due to restricted access. Since the AAA-type B
lgorithm has been introduced, which takes into account the
ateral dispersion caused by the “dense” lung-surrounding tis-
ues, reliable data could be obtained on the doses absorbed by
he tumour and the lung. The AAA algorithm is thought to
rovide an appropriate alternative for MC.20 The algorithms
f PBC and AAA, differ from each other, ﬁrst of all, in the
n-homogenous doses in PTV. The curve of DVH for the PBC
odel pointed to a more  uniform distribution in the target,for the energy of: A/18 MeV,  B/6 MeV.
thus causing no signiﬁcant transgression of doses recom-
mended by IRCU. On the other hand, in AAA calculations
the DVH curve indicated signiﬁcant heterogeneities: exten-
sive regions of low dose appeared, which indicated that in
order to obtain reference doses one had to re-normalize the
DHV curve, obtained in line with AAA calculations, in such a
manner that the minimum and the average doses would ful-
ﬁl conditions of therapeutic doses, and this, in turn, led to
relatively high doses in the region of the tumour and, con-
sequently, elevated the dose to the lung (Fig. 1). Therefore, in
several centres conducting high dose radiotherapy in lung can-
cer the method of prescribing the dose was altered, e.g. from
3 × 20 Gy to 3 × 18 Gy.21
At present, in radiotherapy planning, the use of more
advanced type B algorithms is recommended.14
4.  Techniques  of  IMRT  and  VMAT
Introduction of dose intensity modulation technique (IMRT)
proved to be signiﬁcant for development of radiotherapy, orig-
inally in therapy of tumours located in the head and neck
region. Due to the need for dose escalation with another need
of saving the critical organs, the IMRT technique has also
become an interesting option for lesions located in the chest.
At ﬁrst, due to problems linked to respiratory mobility of the
chest, IMRT was not frequently applied in this location. Due to
the dynamic character of the therapeutic beam, no assurance
could be given whether the elongated duration of treatment,
linked to the implementation of IMRT  schedule, would not
cause an unexpected summation of doses. Nevertheless, the
conducted simulations and statistical analyses demonstrated
that the difference between implementation of 3D plan vs.
IMRT  plan amounts to just around 1%, which was conﬁrmed by
subsequent clinical studies.22 According to IMRT  assumptions,
in most critical organs it is possible to reduce the administered
dose by an average of 18% which, in turn, provides a chance for
dose escalation by around 13%.23 The clinical problem associ-
ated with the IMRT  technique involved low doses of radiation
administered to the healthy lung. In order to evaluate safety
of the treatment, it was necessary to evaluate additional dosi-
metric parameters, e.g. V5 within the lungs. The long-term
observations conducted in MD Anderson centre conﬁrmed
that the application of IMRT allowed to reduce toxicity within
the lungs and oesophagus. Using a 3D planning technique, the
authors detected higher toxicity of the therapy.24
d rad356  reports of practical oncology an
A sophisticated form of IMRT  involves the volumetric mod-
ulated arc therapy (VMAT). Due to such a technique, the dose
becomes deposited during a continuous gantry rotation. The
principle resembles that used in tomotherapy, except that
VMAT may be implemented using a conventional accelerator,
which signiﬁcantly increases the accessibility of the method.
As indicated by investigations, the application of VMAT allows
to obtain a highly conformal plan, as compared to co-planar
and non-co-planar IMRT  techniques.25 Based on our experi-
ence, it can be concluded that the application of VMAT is
particularly useful upon reduced size of the low dose region
(<10%) and, in particular, within the healthy portion of the
tumour-containing lung (Fig. 2). Doses delivered in the tech-
nique to critical organs are appropriately controlled even with
a potential for dose reduction in pulmonary tissue.26 The fact
of the reduced irradiation time, even to <70% of the time
required to implement IMRT  procedure, cannot be overesti-
mated. Due to the frequently applied high dose techniques
(SBRT), it is recommended to use two dynamic arcs in order to
properly distribute the dose in the course of its short admin-
istration. In the other case, extensive inhomogeneities of the
dose may occur, resulting from excessively rapid rotation of
the gantry, movement  of collimator leaves and a variable dose
power (Fig. 3).During irradiation using any of the techniques, despite
precise calculations, a poor deposition of the dose may occur
due to inaccurate placement of the patient or physiological
Fig. 2 – Comparison of 3D and VMAT techniques, for the
region covered by the dose of 10%.
Fig. 3 – The system of two dynamic arcs with dose
distribution.iotherapy 1 9 ( 2 0 1 4 ) 353–360
movements within the body of the patient. As demonstrated
by Purdie,27 extended irradiation times should be avoided: the
author showed that a mean shift of patient’s body depends
on the duration of the procedure and approximates 2.2 mm if
irradiation is administered during up to 34 min. Upon longer
irradiation, the shift may exceed 5 mm.  In such a situation
the appropriate position of the patient should be veriﬁed
again, which in turn additionally extends the procedure and
requires an additional engagement of the staff. Due to its
short duration, the application of VMAT  approach allows to
by-pass the problem.
5.  Treatment  delivery
Until recently, patient set-up was veriﬁed mainly using
megavoltage radiograms, basing on skeletal anatomy. Cur-
rently, many  more  precise and safe methods are available
for appraisal of treatment delivery. One of the more  precise
imaging techniques involves cone-beam CT (CBCT). Such an
imaging allows to visualize not only the bony structures but
also the tumour, with its shifts and positions between frac-
tions. Such an appraisal can and should be conducted both
on-line and off-line.  In the case of stereotactic plan implemen-
tation, just a few fractions are administered and an extremely
accurate veriﬁcation of patient’s position is required: the
standard involves on-line evaluation before every exposure.28
In turn, when conventional fractionation is used, such a pro-
cedure should be applied not more  than, e.g. once a week, due
to the risk of administering an additional dose of irradiation.14
6.  Modiﬁcation  of  radiotherapy
fractionation  schemes
Following the application of deﬁnitive, conventionally frac-
tionated RT, results of treatment in pulmonary carcinoma are
unsatisfactory. One of the possibilities for increasing treat-
ment efﬁcacy involves a change in the manner of fractionation
and, in effect, of the total biological dose of RT. The above
mentioned technological improvements enabled further stud-
ies on increasing treatment efﬁcacy by an increase in the
total dose. The problem of whether administration, in cor-
relation with chemotherapy, of a conventionally fractionated
higher total dose is justiﬁed was resolved by preliminary
results of RTOG 0617 trials. This randomized trial of III phase,
started in 2007 and compared effects of 60 Gy vs. 74 Gy
radiotherapy, accompanied by a concurrent and consolida-
tional chemotherapy (carboplatin/paclitaxel ± cetuximab) in
patients with more  advanced stages (IIIA and B). The total sur-
vival time in the patients amounted to, respectively, 21.4 and
20.7 months with a similar toxicity of the treatment. Although
the multifactorial analysis of the study results conﬁrmed a
comparable toxicity of the applied treatments despite dif-
ferent doses of irradiation, it demonstrated worse results of
treatment in the group of patients with a higher volume of
tumour, in patients with squamous cell carcinoma and with
radiation dose 74 Gy.29 The trial showed that the application
of only slightly augmented dose using a standard form of frac-
tionation brought no expected results.
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.  Hyperfractionated  and  accelerated
adiotherapy
asing on radiotherapeutic premises related to abbreviating
he interval between fractions in order to reduce intensity
f cell repopulation and to reduce the post-irradiation late
eaction in normal tissues, RTOG introduced a number of
tudies on the application of the fractionated dose of 1.2 Gy,
pplied twice daily (hyperfractionation). Improved results of
reatment were noted upon the total dose of 69.6 Gy in 28
ractions, with no further improvement with dose escalation.
ubsequently, this manner of fractionation was compared
n a prospective study comparing hyperfractionated radio-
herapy with standard radiotherapy and with the standard
adiotherapy with induction chemotherapy. A therapeutic
dvantage was detected only in the group receiving induction
hemotherapy. Moreover, subsequent studies of RTOG 9106
nd 9204 manifested another problem affecting the effects
f the applied therapy, the learning curve detected upon the
se of hyperfractionated therapy: in centres treating at least 5
atients per year the mean survival amounted to 20.5 months
hile in the remaining ones it was 13.4 months.30 Most clinical
tudies employing this manner of fractionation were col-
ected by specialists from the Meta-Analysis of Radiotherapy
n Lung Cancer Collaborative Group and subjected to meta-
nalysis. According to the investigators, the application of
yperfractionated radiotherapy and/or accelerated radiothe-
apy improved results of treatment in the form of elongated
-year total survival (OS) by 2.5% although it was burdened
y an increase in toxicity, particularly in the oesophagus.
n additional problem involved organizational difﬁculties
inked to treatment delivery of therapy based on this type of
ractionation.31
.  Hypofractionated  radiotherapy
he above quoted clinical data demonstrate that neither the
ncrease in total dose (upon conventional fractionation) nor
yperfractionation bring the desired effect. Therefore, the
nterest was focused on another model of treatment frac-
ionation, the hypofractionation. Due to improvement in the
arlier described technical aspects of irradiation planning and
mplementation, the precision was increased in determin-
ng the target and reduction of irradiated volumes of critical
rgans (mainly the lungs) which, in effect allowed to apply
igher fractional doses with no escalation of the complica-
ions. The level of hypofractionation may vary, from moderate
doses of 2.4–4 Gy order) to high doses, such as used in stereo-
actic radiotherapy (10–20 Gy per fraction). Both manners of
ractionation continue to be intensely studied. One of the
rospective studies related to hypofractionation is NCIC CTG
R.25 study performed by Cheung et al.33 The patients qual-
ﬁed to the study had T1-3N0M0 tumours, and the planning
mployed 4DCT or ﬂuoroscopy technique for better imaging
f tumour shifts. The recommended dose was 60 Gy with frac-
ionation by 4 Gy. The two-year results of treatment were as
ollows: local control 88%, distant control 76%, total survival
9% at the 3 degree toxicity at the level of 10%. Results oftherapy 1 9 ( 2 0 1 4 ) 353–360 357
treatment were less favourable in the group of patients with
tumour >3 cm,  therefore the justiﬁcation was considered for
chemotherapy administered in parallel to such a fraction-
ation. However, undoubtedly, results of such a scheme of
hypofractionation were better than those of conventionally
fractionated radiotherapy. Therefore, currently a few mul-
ticentre trials are being performed, aimed at determining
signiﬁcance of a moderate hypofractionation for a deﬁnitive
RT (NCT01459497), RT with chemotherapy (NCT01345851) or
with anti-angiogenic drugs (NCT00745732).31
9.  SBRT
A threshold in treatment of lung cancer was provided by
introduction of high fractional doses in studies conducted
at Indiana University by Timmerman. In the studies, using
fractional doses of 20 Gy up to the total dose of 60 Gy for
T1 tumours and 22 Gy for T2 tumours administered on three
fractions, the local control in 2-year follow-up observation
amounted to 95%, giving results comparable to those of surgi-
cal treatment. Toxicity of the treatment approximated 15% for
reactions of 3–4 degree although reaction of 5 degree were also
encountered, mainly within the respiratory system. Studies of
Timmerman et al.34 proved to be of critical value in treatment
of previously inoperable cases of early tumour forms and also
they provided premises for numerous studies in the scope.
Results in most of the studies were surprisingly good: local
relapse <10%, distant metastases <20%, at the toxicity level of
<10%.35 It was signiﬁcant that every of the research centres
applied different fractional doses, distinct ways of normaliza-
tion and also distinct calculation algorithms, frequently even
not described in the studies, which made direct comparisons
between the studies difﬁcult.36
For several years, an improved local efﬁcacy of treatment
has been known to be expected following administration
of a biologically effective dose (BED) ≥100 Gy, with further
improved results at ≥120 Gy or ≥140 Gy.37 At present, most of
fractionation manners take into account this dependence. If
the standard model of dose fractionation according to Tim-
merman in the study of RTOG 0236 is accepted, i.e. 3 × 20 Gy,
the BED amounts to >140 Gy. However, due to the high risk of
toxicity, such fractionation could not be applied for centrally
located tumours, close to the mediastinum. Nevertheless,
numerous groups of investigators, altering the scheme of frac-
tionation, proved safety of SBRT also for centrally located
tumours. Location of the tumour was proved to exert no effect
on survival following SBRT. Also the toxicity level proved to
be acceptable as well as the risk of death linked to this way
of treatment, at the level of <1%.38 The scheme of treatment
which used to be applied in centrally located tumours involves
50 Gy in 5 fractions, 54 Gy in 6 fractions, 60 Gy in 8 fractions.38
In Fig. 4, the typical distribution of 55 Gy dose was presented,
normalized in 80% isodose for PTV region, which permitted to
receive a conformal distribution in GTV-PET, amounting 95%
of the dose in 98% volume.The above mentioned multiplicity of studies with variable
schemes of treatment makes the choice of appropriate man-
ner of fractionation difﬁcult. In this case, studies from the
scope of radiobiology and determination of biological dose
358  reports of practical oncology and rad
Fig. 4 – Normalization of dose for PTV 55 Gy in 80% isodose,
which determines distribution in PET GTV, 95% of the dose
in 98% volume.equivalent (BED) might be helpful. The principal tool for deter-
mining the BED involves the linear-quadratic (LQ) model, the
value of which, however, is restricted for radiotherapy imple-
mented using fractional doses >6 Gy. Basing on experiments
on NSCLC cell lines, the new method of estimating BED was
introduced, based on the universal survival curve (USC). Anal-
ysis of numerous publications related to application of SBRT in
lung cancer, in respect to the relationship between the applied
value of BED and the resulting effects of the therapy, permit-
ted to develop curves, which may be very useful in every day
practice, in selecting an appropriate type of fractionation.39,40
In view of its insigniﬁcant toxicity, SBRT ﬁnds application
in therapy of patients who,  due to co-existing diseases, can-
not be subjected to surgery. In several studies safety of SBRT
was proved in treatment of patients older than 75 years,41
patients with reduced respiratory efﬁciency, e.g. in the course
of chronic obturative pulmonary disease (COPD),42 following
pneumonectomy,43 and even in cases of bilateral lesions in
the lungs.44
In view of the precision of irradiation and application of
high fractional doses in SBRT, a particular attention is given
not only to contouring of target volumes but also to determi-
nation of critical organs. In RT of the lungs, the need appeared
to deﬁne new critical regions and to specify principles of con-
touring involving volumes of protected organs and evaluation
of risk for development of complications. This prompted the
formation of atlases presenting contouring principles.45
In technical terms, SBRT takes advantage of all achieve-
ments of modern technology: planning based on PET-CT, use
of immobilizing systems, determination of targets based on
4D-TK, planning using advanced algorithm, IMRT,  arc tech-
niques, gating and the precise veriﬁcation of position under
the therapeutic machine, e.g. CBCT. Lung stereotactic radio-
therapy uses various techniques of irradiation, depending on
available equipment in a centre and experience of its staff. The
efﬁcacy of SBRT applied at lower advancement stages matches
the results obtained using proton therapy.46
It is worth mentioning that SBRT in early inoperative
lesions in the course of NDRP, in recommendations of
numerous oncological societies, including NCCN and EORTC,
represents at present the standard way of treatment.iotherapy 1 9 ( 2 0 1 4 ) 353–360
Beyond doubt, pulmonary tumours represent cancer with
a high risk of distant metastases, in which stereotactic radio-
therapy is also widely used. Generally known restrictions in
SBRT, depending on size and location of lesions, also apply
to metastatic lesions. Therefore, from the clinical point of
view, it seems signiﬁcant to separate in the group of patients
those with a restricted metastatic form (oligometastasis), in
whom relatively good results of treatment can be obtained.31
Interesting seems to be the concept of separating from the
extensive group of NSCLC patients those in whom tumour
biology favours development of a restricted form of metastatic
disease to whom a more  intense treatment may be sug-
gested. It seems that the differentiating variable might involve
evaluation of microRNA, in particular that belonging to the
microRNA-200 family. Detection of an increased expression
(enhancement) of microRNA-200c may in future provide a
patient-stratifying variable, selecting a group of patients in
whom a more  intense, dedicated radiotherapy is justiﬁed,
using in particular stereotactic procedures.47
10.  Conclusions
Contemporary studies on improvement in treatment of lung
cancer are strictly connected to the enormous technological
progress which has taken place in radiotherapy and in related
branches, including diagnosis. Beyond doubt, optimistic are
results of studies in the group of patients with a tumour of
low advancement in whom the chance exists to perform SBRT.
Results of studies on the application of this form of treatment
prove that desired effects may be obtained only when bio-
logically effective doses ≥100 Gy are applied. Studies should
continue on other forms of radiotherapy hypofractionation,
particularly in association with chemotherapy, which might
improve results of treatment in patients with more  advanced
stages of the disease. In order to reduce mortality induced by
lung cancer a high stress on primary prevention should con-
tinuously be exerted, particularly involving efforts to reduce
the proportion of smokers and this goal should also fall within
the scope of oncologists’ activities. More attention should be
paid to increased frequency of early diagnosis in lung can-
cer and, therefore, start of its treatment at an early stage of
the disease, which is a basic condition for an effective ther-
apy. Technical potential for diagnosis and treatment expands,
although in their every day practice oncologists who  deal with
treatment of lung cancer still face the problem of an appropri-
ately rapid access to modern diagnostic tools and, in effect, the
potential to introduce an effective therapy. Like in the case
of breast cancer, multidisciplinary teams should be formed
dealing in a complex manner with problems of diagnosis and
treatment of patients with lung cancer. Only the common
activities of the entire team of specialists, supported by appro-
priate organizational processes may lead to improvement in
results of treatment in patients with lung cancer.Conﬂict  of  interest
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